Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Real-World Retrospective Study of Non-Transfusion Dependent Patients with Myelodysplastic Syndromes Treated with Luspatercept: A Healthcare Claims Database Study

Leslie A. Andritsos, Kirollos S. Hanna, Enrico Zanardo, Ali McBride, Victoria Barghout, Rui Song, Lynn Huynh, Derek Tang, Mihran Yenikomshian, Kashyap Patel

Blood (2023) 142 (Supplement 1): 3808.

https://doi.org/10.1182/blood-2023-173375

Published: 2023

Journal Articles

Real-World Impact of Luspatercept on Patients with Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions and with Prior Exposure to Erythropoietin-Stimulating Agents: A United States Healthcare Claims Database Study

Kashyap Patel, Kirollos S. Hanna, Enrico Zanardo, Ali McBride, Victoria Barghout, Rui Song, Lynn Huynh, Derek Tang, Mihran Yenikomshian, Leslie A. Andritsos

Blood (2023) 142 (Supplement 1): 916.

https://doi.org/10.1182/blood-2023-173364

Published: 2023

Journal Articles

Retrospective Analysis of Residual Hairy Cell Leukemia Measured By IHC or Flow Cytometry and Frontline Treatment with Pentostatin on Time to Next Treatment

Andrew Stiff, Qiuhong Zhao, Nilesh Kapoor, Kerry A. Rogers, Mirela Iulia Anghelina, Jasmine Neal, Leslie A. Andritsos, James S. Blachly, Gerard Lozanski, Michael R. Grever, Seema A. Bhat

Blood (2022) 140 (Supplement 1): 6524–6525.

https://doi.org/10.1182/blood-2022-166619

Published: 2022

Journal Articles

Incidence, Description, and Timing of Serious or Opportunistic Infections in Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogues

Nilesh Kapoor, Qiuhong Zhao, Andrew Stiff, Seema A. Bhat, Mirela Iulia Anghelina, Jasmine Neal, Leslie A. Andritsos, James S. Blachly, Narendranath Epperla, Zeinab El Boghdadly, Michael R. Grever, Kerry A. Rogers

Blood (2022) 140 (Supplement 1): 9361–9362.

https://doi.org/10.1182/blood-2022-156720

Published: 2022

Journal Articles

Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia

Kerry A. Rogers, Eric McLaughlin, Lai Wei, Mirela Iulia Anghelina, Mir Khader Ali, Leslie A. Andritsos, Evgeny Arons, James S. Blachly, Timothy G. Call, S. Percy Ivy, Lacey James-Echenique, Jeffrey A. Jones, Robert J. Kreitman, Gerard Lozanski, Farhad Ravandi, Charles A. Schiffer, William E. Carson, III, Michael R. Grever

Blood (2022) 140 (Supplement 1): 6494–6495.

https://doi.org/10.1182/blood-2022-165795

Published: 2022

Journal Articles

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

Blood (2021) 137 (25): 3473–3483.

https://doi.org/10.1182/blood.2020009688

Published: 2021

Includes: Supplemental data

Journal Articles

Racial and Ethnic Differences in Incidence and Disease Specific Survival of Multiple Myeloma- New Mexico Tumor Registry Based Study

Shashank R Cingam, MBBS, Martha Mapalo, MD, Meisner L Angela, MPH, Charles Wiggins, PhD, Leslie A. Andritsos, MD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-139095

Published: 2020

Journal Articles

Down-Regulation of CD25 Antigen in Hairy Cell Leukemia Patients after Treatment

Mirela Anghelina, Narendranath Epperla, MD MS, Kerry A. Rogers, MD, Ling Guo, MD, Qiuhong Zhao, MS, James S. Blachly, MD, David M. Lucas, PhD, Christopher C. Oakes, Gerard Lozanski, MD, Michael R. Grever, MD, Leslie A. Andritsos, MD

Blood (2018) 132 (Supplement 1): 4143.

https://doi.org/10.1182/blood-2018-99-120043

Published: 2018

Journal Articles

Toxigenic Clostridium Difficile Colonization in Patients with Hematologic Malignancies Admitted to the Hospital for Chemotherapy or Hematopoietic Cell Transplantation

John L Vaughn, MD, Misty Lamprecht, MS, Ying Huang, MA, MS, Mirela Anghelina, Joan-Miquel Balada-Llasat, PharmD, PhD, Zeinab El Boghdadly, MBBCh, Rachel Childs, Preeti Pancholi, PhD, Leslie A Andritsos, MD

Blood (2017) 130 (Supplement 1): 3211.

https://doi.org/10.1182/blood.V130.Suppl_1.3211.3211

Published: 2017

Journal Articles

Response Rates, Non-Relapse Mortality, and Financial Implications of Transplant-Associated Thrombotic Microangiopathy Treated with Eculizumab

Blood (2017) 130 (Supplement 1): 1932.

https://doi.org/10.1182/blood.V130.Suppl_1.1932.1932

Published: 2017

Journal Articles

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Blood (2017) 129 (5): 553–560.

https://doi.org/10.1182/blood-2016-01-689422

Published: 2017

Journal Articles

A Distributed International Patient Data Registry for Hairy Cell Leukemia

Leslie A. Andritsos, MD, Michael R. Grever, MD, Mirela Anghelina, MD, Claire E Dearden, MD FRCP, FRCPath, Monica Else, MA, MSc, James S. Blachly, MD, Omkar Lele, MS, MBA, Farhad Ravandi, MD, Clive S Zent, MD, James B. Johnston, MD FRCP, Versha Banerji, MD FRCP, Francesco Forconi, MD DM, PhD FRCPath, Anthony D. Ho, MD, Thorsten Zenz, Sascha Dietrich, Judit Demeter, MD PhD, Jacqueline C. Barrientos, MD, Jan A. Burger, MD PhD, Timothy G. Call, MD, Nicholas Chiorazzi, MD, Daniel J. DeAngelo, MD PhD, Julio Delgado, MD, Andrei Fagarasanu, MD PhD, Brunangelo Falini, Alessandro Gozzetti, MD, Jeffrey Jones, MD MPH, Gunnar Juliusson, MD, Eric H. Kraut, MD, Robert J. Kreitman, MD, Loree Larratt, MD, Francesco Lauria, MD, Gerard Lozanski, MD, Emili Montserrat, MD, Sameer A. Parikh, MD, Jae H. Park, MD, Aaron Polliack, MD, Graeme R. Quest, MD MSc, Kanti R. Rai, MD, Tadeusz Robak, MD PhD, Alan Saven, MD, Tamar Tadmor, MD, Martin S. Tallman, MD, Constantine S. Tam, MBBS, Enrico Tiacci, MD, Xavier Troussard, MD PhD, Omar Abdel-Wahab, MD, Pier Luigi Zinzani, MD, PhD, Christopher Heckler, BS, MBA, Philip R.O. Payne, PhD

Blood (2016) 128 (22): 5986.

https://doi.org/10.1182/blood.V128.22.5986.5986

Published: 2016

Journal Articles

A Retrospective Evaluation of the Impact of Pre-Emptive Plerixafor Administration on Collection Efficiency in Patients with Myeloma Undergoing Stem Cell Mobilization

Leslie A. Andritsos, MD, Ying Huang, MA, MS, Tao Fan, PhD, Keith Huff, PharmD, Ed Drea, PharmD, Ali McBride, PharmD,MS

Blood (2016) 128 (22): 5740.

https://doi.org/10.1182/blood.V128.22.5740.5740

Published: 2016

Journal Articles

Psychosocial Risk Is Associated with High Readmission Rates and Increased Length of Stay for Patients Following Hematopoietic Stem Cell Transplantation

Daniel R Richardson, MD, Ying Huang, MA, MS, Patrick Elder, MS, Joanna Newlin, LISW, Cyndi Kirkendall, LISW, Steven M Devine, MD, Leslie A. Andritsos, MD, Don M Benson, MD PhD, William Blum, MD, Yvonne A Efebera, MD MPH, Craig C Hofmeister, Samantha Jaglowski, MD MPH, Rebecca B Klisovic, MD, Heather L McGinty, PhD, Sam Penza, MD, Sumithra Vasu, MBBS, Basem M William, MD, Ashley E Rosko, MD

Blood (2016) 128 (22): 1241.

https://doi.org/10.1182/blood.V128.22.1241.1241

Published: 2016

Journal Articles

Cytomegalovirus Reactivation Does Not Increase Subsequent Risk for Acute Graft-Versus-Host Disease, Malignant Disease Relapse, or Infection Following Allogeneic Hematopoietic Cell Transplantation

Blood (2016) 128 (22): 3409.

https://doi.org/10.1182/blood.V128.22.3409.3409

Published: 2016

Journal Articles

Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism

Meixiao Long, MD PhD, Kyle A. Beckwith, PhD, Priscilla Do, BS, Mundy L Bethany, PhD, Gordon Gordon, Amy M. Lehman, MAS, Kami J. Maddocks, MD, Carolyn Cheney, BS, Jeffrey Jones, MD MPH, Leslie A. Andritsos, MD, Farrukh T. Awan, Joseph A. Fraietta, PhD, Carl H June, MD, Marcela V. Maus, MDPhD, Jennifer A. Woyach, MD, Michael A. Caligiuri, MD, Amy J. Johnson, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2016) 128 (22): 3238.

https://doi.org/10.1182/blood.V128.22.3238.3238

Published: 2016

Journal Articles

Early Infection Attenuates Hematologic Malignant Disease Relapse Following Initial Allogeneic Hematopoietic Cell Transplantation

Blood (2016) 128 (22): 3410.

https://doi.org/10.1182/blood.V128.22.3410.3410

Published: 2016

Journal Articles

Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib

Blood (2016) 128 (22): 3198.

https://doi.org/10.1182/blood.V128.22.3198.3198

Published: 2016

Journal Articles

Trametinib for the Treatment of IGHV4-34, MAP2K1 Mutant Variant Hairy Cell Leukemia

Leslie A. Andritsos, MD, Mirela Anghelina, MD, Nicole R. Grieselhuber, MD PhD, Sameek Roychowdhury, MD PhD, Julie Reeser, PhD, Cynthia Timmers, PhD, Aharon G. Freud, MD PhD, James S. Blachly, MD, David M. Lucas, PhD, Gerard Lozanski, MD, Jeffrey Jones, MD MPH, Kerry A. Rogers, MD, Weiqiang Zhao, MD PhD, Michael R. Grever, MD

Blood (2016) 128 (22): 5598.

https://doi.org/10.1182/blood.V128.22.5598.5598

Published: 2016

Journal Articles

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Blood (2016) 128 (22): 55.

https://doi.org/10.1182/blood.V128.22.55.55

Published: 2016

NARROW

Real-World Retrospective Study of Non-Transfusion Dependent Patients with Myelodysplastic Syndromes Treated with Luspatercept: A Healthcare Claims Database Study

Real-World Impact of Luspatercept on Patients with Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions and with Prior Exposure to Erythropoietin-Stimulating Agents: A United States Healthcare Claims Database Study

Retrospective Analysis of Residual Hairy Cell Leukemia Measured By IHC or Flow Cytometry and Frontline Treatment with Pentostatin on Time to Next Treatment

Incidence, Description, and Timing of Serious or Opportunistic Infections in Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogues

Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

Racial and Ethnic Differences in Incidence and Disease Specific Survival of Multiple Myeloma- New Mexico Tumor Registry Based Study

Down-Regulation of CD25 Antigen in Hairy Cell Leukemia Patients after Treatment

Toxigenic Clostridium Difficile Colonization in Patients with Hematologic Malignancies Admitted to the Hospital for Chemotherapy or Hematopoietic Cell Transplantation

Response Rates, Non-Relapse Mortality, and Financial Implications of Transplant-Associated Thrombotic Microangiopathy Treated with Eculizumab

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

A Distributed International Patient Data Registry for Hairy Cell Leukemia

A Retrospective Evaluation of the Impact of Pre-Emptive Plerixafor Administration on Collection Efficiency in Patients with Myeloma Undergoing Stem Cell Mobilization

Psychosocial Risk Is Associated with High Readmission Rates and Increased Length of Stay for Patients Following Hematopoietic Stem Cell Transplantation

Cytomegalovirus Reactivation Does Not Increase Subsequent Risk for Acute Graft-Versus-Host Disease, Malignant Disease Relapse, or Infection Following Allogeneic Hematopoietic Cell Transplantation

Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism

Early Infection Attenuates Hematologic Malignant Disease Relapse Following Initial Allogeneic Hematopoietic Cell Transplantation

Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib

Trametinib for the Treatment of IGHV4-34, MAP2K1 Mutant Variant Hairy Cell Leukemia

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only